Takeda announces phase 3 topline results for soticlestat (tak-935) in patients with dravet syndrome and lennox-gastaut syndrome

Osaka, japan & cambridge, mass.--(business wire)--takeda (tse:4502/nyse:tak) today announced topline data from its skyline and skyway studies. skyline (tak-935-3001) was a multicenter, randomized, double-blind phase 3 study that evaluated soticlestat (tak-935) plus standard of care versus placebo plus standard of care in patients with refractory dravet syndrome (ds).1 soticlestat narrowly missed the primary endpoint of reduction from baseline in convulsive seizure frequency as compared to place.
TAK Ratings Summary
TAK Quant Ranking